Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive carcinoma arising from the ovary. Most patients present with advanced disease. Microscopically, it is characterized by significant cytologic atypia, increased mitotic activity, and necrosis. The prognosis is usually poor.
Biomarker and diagnostic research for undifferentiated ovarian carcinoma has been reported in the published literature.
9 clinical trials registered. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 4 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02502266](https://clinicaltrials.gov/study/NCT02502266) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer |
PHASE2 |
National Cancer Institute (NCI) |
UNKNOWN |
[NCT02839707](https://clinicaltrials.gov/study/NCT02839707) | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PHASE2 | National Cancer Institute (NCI) | UNKNOWN |
[NCT04739800](https://clinicaltrials.gov/study/NCT04739800) | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | PHASE2 | National Cancer Institute (NCI) | UNKNOWN |
[NCT00565851](https://clinicaltrials.gov/study/NCT00565851) | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | PHASE3 | National Cancer Institute (NCI) | UNKNOWN |
[NCT04092270](https://clinicaltrials.gov/study/NCT04092270) | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | PHASE1 | National Cancer Institute (NCI) | UNKNOWN |
106 publications have been identified in PubMed for undifferentiated ovarian carcinoma. Research spans Review / Meta-Analysis (34%), Basic Science / Preclinical (22%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 31 | 34% |
Laboratory research | 20 | 22% |
Patient case studies | 15 | 16% |
Clinical study results | 9 | 10% |
Disease patterns and progression | 8 | 9% |
Testing and diagnosis research | 7 | 8% |
New treatment approaches | 1 | 1% |
Bansal D (2026). [PMID: 42147566](https://pubmed.ncbi.nlm.nih.gov/42147566/). *Cureus*. [Case Report / Case Series]
Grimes WR (2026). [PMID: 33085416](https://pubmed.ncbi.nlm.nih.gov/33085416/). *Unknown Journal*. [Basic Science / Preclinical]
Gu Z (2026). [PMID: 41593759](https://pubmed.ncbi.nlm.nih.gov/41593759/). *J Med Case Rep*. [Case Report / Case Series]
Sun Y (2026). [PMID: 41906161](https://pubmed.ncbi.nlm.nih.gov/41906161/). *BMC Womens Health*. [Case Report / Case Series]
Jiang W (2026). [PMID: 41935983](https://pubmed.ncbi.nlm.nih.gov/41935983/). *Discov Oncol*. [Basic Science / Preclinical]
Scott CL (2026). [PMID: 41786760](https://pubmed.ncbi.nlm.nih.gov/41786760/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Chae YK (2026). [PMID: 41672597](https://pubmed.ncbi.nlm.nih.gov/41672597/). *J Immunother Cancer*. [Clinical Trial Publication]
Mezzapesa F (2026). [PMID: 40685312](https://pubmed.ncbi.nlm.nih.gov/40685312/). *Int J Gynecol Cancer*. [Epidemiology / Natural History]
Lugata J (2026). [PMID: 41704940](https://pubmed.ncbi.nlm.nih.gov/41704940/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Avsar H (2026). [PMID: 42049331](https://pubmed.ncbi.nlm.nih.gov/42049331/). *Anticancer Res*. [Case Report / Case Series]
AI-curated news mentioning undifferentiated ovarian carcinoma
Updated Jul 21, 2026
A recent publication discusses fertility-sparing surgery in young women diagnosed with ovarian anaplastic carcinoma, presenting two case reports alongside a literature review. This research highlights potential surgical options for preserving fertility in this patient population.